UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Clinical cancer research, 2009-04, Vol.15 (7), p.2514-2522

2009

Volltextzugriff (PDF)

Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function

Glycoconjugate journal, 2011-05, Vol.28 (3-4), p.137-147

2011

Volltextzugriff (PDF)

Modulation of Growth Factor Signaling by Gangliosides: Positive Or Negative?

Methods in Enzymology, 2006, Vol.417, p.168-185

2006

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Investigational new drugs, 2008-02, Vol.26 (1), p.35-43

2008

Volltextzugriff (PDF)

Low complex ganglioside expression characterizes human neuroblastoma cell lines

Cancer letters, 2005-07, Vol.225 (1), p.141-149

2005

Volltextzugriff (PDF)

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients

Blood, 2009-11, Vol.114 (22), p.2670-2670

2009

Volltextzugriff (PDF)

Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression

Cancer research (Chicago, Ill.), 2003-11, Vol.63 (21), p.7270-7276

2003

Volltextzugriff (PDF)

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL)

Blood, 2009-11, Vol.114 (22), p.839-839

2009

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia

Blood, 2009-11, Vol.114 (22), p.888-888

2009

Volltextzugriff (PDF)

EBV-Related Lymphoproliferative Disease ComplicatingTherapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients withT-Cell Malignancies

Clinical cancer research, 2009-03, Vol.15 (7), p.2514-2522

2009

Volltextzugriff (PDF)

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies

Blood, 2007-11, Vol.110 (11), p.3565-3565

2007

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of etaracizumab (Abegrin registered ), a humanized monoclonal antibody against alpha sub(v) beta sub(3) integrin receptor, in patients with advanced solid tumors

Investigational new drugs, 2008-02, Vol.26 (1), p.35-43

2008

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of etaracizumab (Abegrin(TM)), a humanized monoclonal antibody against [alpha]v[beta]3 integrin receptor, in patients with advanced solid tumors

Investigational new drugs, 2008-02, Vol.26 (1), p.35

2008

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors

Investigational new drugs, 2008-02, Vol.26 (1), p.35

2008

Volltextzugriff (PDF)

Biological stratification of human neuroblastoma by complex B pathway ganglioside expression1

Cancer research (Chicago, Ill.), 2003, Vol.63 (21), p.7270-7276

2003

Volltextzugriff (PDF)

Neuroblastomas of infancy exhibit a characteristic ganglioside pattern

Cancer, 2001-02, Vol.91 (4), p.785-793

2001

Volltextzugriff (PDF)

Growth Regulation in Hematopoietic Cells Is Partially Mediated by Double Stranded RNA-Dependent Protein Kinase

Pediatric research, 1999-04, Vol.45 (4, Part 2 of 2), p.148-148A

1999

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(8)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Oncology
(6)
Neuroblastoma - Pathology
(4)
Biochemistry & Molecular Biology
(3)
Biological And Medical Sciences
(3)
Cancer
(3)
Gangliosides - Biosynthesis
(3)
Medical Sciences
(3)
Neuroblastoma
(3)
Neuroblastoma - Metabolism
(3)
Patients
(3)
Tumors
(3)
Aged
(2)
Angiogenesis
(2)
Antibodies, Monoclonal - Adverse Effects
(2)
Antibodies, Monoclonal, Humanized
(2)
Antineoplastic Agents
(2)
Carbohydrate Sequence
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Induction of GM1a/GD1b synthase triggers complex ganglioside expression and alters neuroblastoma cell behavior; a new tumor cell model of ganglioside function

Modulation of Growth Factor Signaling by Gangliosides: Positive Or Negative?

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Low complex ganglioside expression characterizes human neuroblastoma cell lines

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients

Biological stratification of human neuroblastoma by complex "B" pathway ganglioside expression

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL)

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia

EBV-Related Lymphoproliferative Disease ComplicatingTherapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients withT-Cell Malignancies

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies

Phase I and pharmacokinetic study of etaracizumab (Abegrin registered ), a humanized monoclonal antibody against alpha sub(v) beta sub(3) integrin receptor, in patients with advanced solid tumors

Phase I and pharmacokinetic study of etaracizumab (Abegrin(TM)), a humanized monoclonal antibody against [alpha]v[beta]3 integrin receptor, in patients with advanced solid tumors

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors

Biological stratification of human neuroblastoma by complex B pathway ganglioside expression1

Neuroblastomas of infancy exhibit a characteristic ganglioside pattern

Growth Regulation in Hematopoietic Cells Is Partially Mediated by Double Stranded RNA-Dependent Protein Kinase

Suchergebnisse filtern